Those large AH price moves for BMY and PFE are not crazy insofar as Eliquis has the potential to be a very big-selling drug. The drop in Bayer’s share price today seems a bit excessive, however.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”